Copertina

Bruton tyrosine kinase inhibitor monotherapy in B‐cell lymphoma and risk of infection: A systematic review and meta‐analysis of randomized controlled trials

Fuente: Wiley Open Access

Salvato in:

Dettagli Bibliografici
Autori principali:	Mohammed Zuber, Samruddhi Nandkumar Borate, Pooja Gokhale, Akhila Yerubandi, N. M. Mahmudul Alam Bhuiya, Smita Rawal, Henry N. Young, Lorenzo Villa Zapata
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2024
Soggetti:	Hematological Oncology
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

Unmet needs in relapsed/refractory mantle cell lymphoma after failure of covalent Bruton's tyrosine kinase inhibitors: An Italian scenario
di: Antonio Pinto, et al.
Pubblicazione: (2024)

How receptor tyrosine kinase‐like orphan receptor 1 meets its partners in chronic lymphocytic leukemia
di: Nayla Mouawad, et al.
Pubblicazione: (2024)

Role of gut microbiome in the outcome of lymphoma patients treated with checkpoint inhibitors—The MicroLinf Study
di: Beatrice Casadei, et al.
Pubblicazione: (2024)

Prognostic relevance of circulating lymphoma cells at diagnosis in newly diagnosed follicular lymphoma patients
di: Kaitlin Annunzio, et al.
Pubblicazione: (2024)

Clinical characteristics and outcome of early‐stage diffuse large B cell lymphoma of female genital track: A retrospective study of the Hellenic cooperative lymphoma group
di: Evgenia Verrou, et al.
Pubblicazione: (2024)

Safety and effectiveness of mogamulizumab in relapsed or refractory CC chemokine receptor 4‐positive peripheral T‐cell lymphoma and relapsed or refractory cutaneous T‐cell lymphoma: A post‐marketing surveillance in Japan
di: Kenji Ishitsuka, et al.
Pubblicazione: (2024)

Characterizing second line and beyond therapies for primary central nervous system lymphomas
di: Brian Primeaux, et al.
Pubblicazione: (2024)

New insights into the Bortezomib‐induced cytotoxic and resistance mechanisms in a primary effusion lymphoma mouse model
di: Maria Anele Romeo, et al.
Pubblicazione: (2024)

Antibody targeting of surface P‐selectin glycoprotein ligand 1 leads to lymphoma apoptosis and tumorigenesis inhibition
di: João L. Pereira, et al.
Pubblicazione: (2024)

Treatment patterns, clinical outcomes and gene mutation characteristics of hepatitis B virus‐associated mantle cell lymphoma
di: Jiangfang Feng, et al.
Pubblicazione: (2024)

Metabolic pathway‐based subtyping reveals distinct microenvironmental states associated with diffuse large B‐cell lymphoma outcomes
di: Xiaohui Wang, et al.
Pubblicazione: (2024)

Texture analysis of 18F‐FDG PET/CT and CECT: Prediction of refractoriness of Hodgkin lymphoma with mediastinal bulk involvement
di: Elisabetta M. Abenavoli, et al.
Pubblicazione: (2024)

The role of baseline 2‐[ 18 F]‐FDG‐PET/CT metrics and radiomics features in predicting primary gastric lymphoma diagnosis
di: Domenico Albano, et al.
Pubblicazione: (2024)

Efficacy of escalating therapy with brentuximab vedotin‐AVD in advanced stage Hodgkin lymphoma patients with positive interim positron emission tomography after ABVD
di: Carmen Martínez, et al.
Pubblicazione: (2024)

873 | DISPARITIES IN LYMPHOMA TREATMENT ACCESS AT RIAU, ONE OF PROVINCE IN INDONESIA: WHEN LATE DIAGNOSIS AND UNEQUAL CARE DEFINE OUTCOMES
di: N. N. M. Nasution, et al.
Pubblicazione: (2025)

Possible effects of plasminogen activator inhibitor‐1 on promoting angiogenesis through matrix metalloproteinase 9 in advanced mycosis fungoides
di: Taku Fujimura, et al.
Pubblicazione: (2024)

Outcomes after treating advanced mantle cell lymphoma in a low‐income group at a Latin American center: The role of outpatient hematopoietic stem cell transplantation
di: José Carlos Jaime‐Pérez, et al.
Pubblicazione: (2024)

Allogeneic transplantation for adult T‐cell leukemia/lymphoma in adolescent and young adults and young patients: A nationwide retrospective study by the ATL working group of the Japan society for transplantation and cellular therapy
di: Hidehiro Itonaga, et al.
Pubblicazione: (2024)

878 | DEVELOPING AN OUTPATIENT BISPECIFIC ANTIBODY THERAPY PROGRAM: INFRASTRUCTURE AND TOOLS FROM THE JOHNS HOPKINS SIDNEY KIMMEL COMPREHENSIVE CANCER CENTER
di: N. Shafagati, et al.
Pubblicazione: (2025)

Evaluation of participation and recruitment bias in a prospective Real World Data in Lymphoma and Survival in Adults (REALYSA) cohort for newly diagnosed lymphoma patients over 1 year in a hematology department of teaching hospital
di: Caroline Le Lan, et al.
Pubblicazione: (2024)

564 | ADHERENCE TO THE 2‐YEAR MAINTENANCE THERAPY PROTOCOL WITH ANTI‐CD20 MONOCLONAL ANTIBODIES POSITIVELY IMPACTS CLINICAL OUTCOMES OF FOLLICULAR LYMPHOMA PATIENTS
di: S. Ringelstein‐Harlev, et al.
Pubblicazione: (2025)

685 | DRUG PRESCRIPTIONS FOR PERIPHERAL NEUROPATHY AND GASTROINTESTINAL EVENTS IN FIRST‐LINE POLA‐R‐CHP FOR ELDERLY DLBCL PATIENTS INCLUDING THOSE AGED 80+ IN JAPAN
di: Y. Saito, et al.
Pubblicazione: (2025)

421 | ctDNA DYNAMICS OF REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA
di: R. N. Rys, et al.
Pubblicazione: (2025)

Secondary acute myeloid leukemia and early infection are independent predictors of poor survival in acute myeloid leukemia treated with hypomethylating agents and venetoclax
di: Stefano Cordella, et al.
Pubblicazione: (2024)

Analyzing the risk factors for disease progression within 2 years and histological transformation in patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone as first‐line treatment: A 15‐year follow‐up of patients with advanced follicular lymphoma in JCOG0203
di: Takashi Watanabe, et al.
Pubblicazione: (2024)

641 | OUTCOMES OF DOSE ADJUSTED R‐EPOCH IN ELDERLY PATIENTS: A RETROSPECTIVE STUDY
di: G. Kaleka, et al.
Pubblicazione: (2025)

738 | SURFACEOME PROFILING FOR THE IDENTIFICATION OF NOVEL IMMUNOTHERAPEUTIC TARGETS IN NATURAL KILLER/T CELL LYMPHOMA
di: E. S. Chew, et al.
Pubblicazione: (2025)

546 | PATIENT REPORTED OUTCOMES AND PREDICTORS OF INHIBITOR USE IN CHRONIC LYMPHOCYTIC LEUKEMIA—AN ANALYSIS OF THE LYMPHOMA COALITION’S 2024 GLOBAL PATIENT SURVEY
di: S. E. Kalloger, et al.
Pubblicazione: (2025)

597 | ORELABRUTINIB COMBINED WITH ANTI‐CD20 MONOCLONAL ANTIBODIES IS HIGHLY EFFECTIVE AND WELL TOLERATED AS FIRST‐LINE THERAPY FOR MARGINAL ZONE B CELL LYMPHOMA
di: L. Wang, et al.
Pubblicazione: (2025)

118 | CDK7 ENABLES THE FUNCTIONAL CROSSTALK BETWEEN LYMPHOMA AND MICROENVIRONMENT (TME) CELLS IN PERIPHERAL T‐CELL LYMPHOMA (PTCL)
di: K. Kouidri, et al.
Pubblicazione: (2025)

737 | COST IMPLICATIONS OF REPRODUCTIVE OUTCOMES IN HODGKIN’S LYMPHOMA PATIENTS RECEIVING FIRST‐LINE TREATMENT FROM THE DENMARK NATIONAL HEALTHCARE AND SOCIETAL PERSPECTIVES
di: M. Hutchings, et al.
Pubblicazione: (2025)

570 | EFFICACY AND SAFETY OF SUBCUTANEOUS MOSUNETUZUMAB MONOTHERAPY AND IN COMBINATION WITH LENALIDOMIDE IN JAPANESE PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA
di: D. Maruyama, et al.
Pubblicazione: (2025)

404 | CLINICAL RELEVANCE OF PERIPHERAL BLOOD MEASURABLE RESIDUAL DISEASE ASSESSMENT IN NEWLY DIAGNOSED MULTIPLE MYELOMA AFTER INITIAL THERAPY: A PROSPECTIVE STUDY
di: G. Chatterjee, et al.
Pubblicazione: (2025)

687 | OUTCOMES IN PATIENTS WITH POST‐TRANSPLANT LYMPHOPROLIFERATIVE DISORDER: THE VIRGINIA COMMONWEALTH UNIVERSITY EXPERIENCE
di: V. Yazbeck, et al.
Pubblicazione: (2025)

479 | DLBCL‐ASSOCIATED PIM1 MUTATION DRIVES ANXA2 RELOCATION ON THE MEMBRANE AND PROMOTES LYMPHOMAGENESIS
di: Y. Lu, et al.
Pubblicazione: (2025)

842 | MYHODGKIN MYHEALTH SURVIVORSHIP APP RECRUITMENT SUGGESTS HIGH ACCEPTABILITY OF PATIENT‐DERIVED DATA IN HODGKIN LYMPHOMA
di: N. Wong Doo, et al.
Pubblicazione: (2025)

884 | THE EMOTIONAL BURDEN OF LYMPHOMA: HOW LYMPHOMA SURVIVORS PERCEIVE RELATIONSHIPS AND SELF‐IMAGE
di: N. Shokun, et al.
Pubblicazione: (2025)

97 | MUTATION SIGNATURES INVOLVING EPIGENETIC MODIFIERS PREDICT FOLLICULAR LYMPHOMA RESPONSE TO RADIOTHERAPY
di: N. A. Wijetunga, et al.
Pubblicazione: (2025)

705 | POINT OF CARE ANTI‐CD19 CART CELLS FOR PRIMARY AND SECONDARY CNS LYMPHOMA—THE EXPERIENCE OF A SINGLE CENTER COHORT
di: N. Golan‐Accav, et al.
Pubblicazione: (2025)

121 | INFLUENCE OF HEALTH DISPARITIES (HD) ON CLINICAL OUTCOMES IN PATIENTS (PTS) WITH DIFFUSE LARGE B CELL LYMPHOMA (DLBCL) IN THE UNITED STATES
di: A. J. Alencar, et al.
Pubblicazione: (2025)